Model‐Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value‐Based Healthcare
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70270 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Rajesh Krishna und 4 weiteren Autor:innen. Beteiligte Einrichtung: Certara Drug Development Solutions, Certara USA, Inc., Radnor, PA, USA. Hauptthemen laut MEDLINE: Drug Discovery, Pharmacology, Clinical, Decision Making. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The transition to value‐based healthcare demands more efficient, evidence‐driven approaches to drug discovery, development and medical use. Clinical pharmacology is uniquely positioned to support this shift through model‐informed drug development (MIDD) decision‐making, integrating quantitative methods across the product lifecycle. This commentary outlines a roadmap for embedding MIDD from early drug discovery through regulatory evaluation and ultimately into reimbursement and real‐world use. We highlight how pharmacokinetic/pharmacodynamic modeling, mechanistic modeling, disease progression models, patient‐relevant endpoints, and real‐world data will inform dose selection, optimize trial design, and reduce uncertainty in benefit–risk and cost‐effectiveness assessments. Emphasis is placed on cross‐stakeholder alignment, including regulators, payers, clinicians, and industry, to ensure that model‐informed evidence translates into demonstrable patient and economic value. Key challenges, such as data integration, model transparency, and acceptance by decision‐makers, are discussed alongside practical solutions. By advancing a lifecycle‐based, quantitatively informed framework, clinical pharmacology can play a central role in delivering therapies that are not only safe and effective but also aligned with the principles of value‐based healthcare.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Certara Drug Development Solutions, Certara USA, Inc., Radnor, PA, USA.
- Certara Predictive Technologies, Certara, Sheffield, UK.
ORCID-Profile: Rajesh Krishna, Fran Brown
Zitieren
APA
Krishna, R., Kadambi, A., Smith, P., van der Graaf, P. H., & Brown, F. (2026). Model‐Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value‐Based Healthcare. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70270
Vancouver
Krishna R, Kadambi A, Smith P, van der Graaf PH, Brown F. Model‐Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value‐Based Healthcare. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70270
BibTeX
@article{Krishna2026,
author = {Krishna, Rajesh and Kadambi, Ananth and Smith, Patrick and van der Graaf, Piet H and Brown, Fran},
title = {Model‐Informed Decision Making from Drug Discovery to Reimbursement: A Roadmap for Clinical Pharmacology in Value‐Based Healthcare},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70270}
}
EUVIMED